Fundz Deep Dive
Everything you need to win Nurix Therapeutics — in one platform.
Who to reach, what to say, and why now on Nurix Therapeutics — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on Nurix Therapeutics — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
Ready now? Choose your plan · Request a demo · Sign in
Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.
Nurix Therapeutics Partners with Roche to Develop Bexobrutideg for B-Cell Malignancies
Jun 08, 2026•8 days ago
Contract Type
partnership
San FranciscoOtherBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaDescription
Nurix Therapeutics has announced a global collaboration with Roche to develop bexobrutideg, a novel therapy for B-cell malignancies. The partnership includes a robust clinical development plan with a total potential value of $2.3 billion, incorporating both hematology and plans for trials in neurology and immunology.
Related People
Suggested for you
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months